A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
← catalyst calendarNCT07073820 · readout in 699 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
36estimated
Sites
48
Countries
Australia, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-10 | actual | When the study began enrolling |
| Primary completion | 2028-07-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Hypertension
Intervention
- Drug: PF-07868489
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Baseline up to week 111
Number of Participants With Change From Baseline in Laboratory Tests Results
measured Baseline up to week 111
Number of Participants With Vital Sign Abnormalities
measured Baseline up to week 111
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed